Taking people in JapanNo phase

Observes safety of once-weekly insulin icodec in people with type 1 diabetes

Follows people with type 1 diabetes receiving once-weekly insulin icodec as prescribed in Japan.

Plain-language title generated from the registry record
Registry title: General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

Key facts

Where: Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime, Fukuoka, Gifu, Gunma, Hiroshima, Hokkaido, Hyōgo, Hyogogoken, Ibaraki, Kagawa, Kagoshima-shi, Kagoshima, Kanagawa, Kisarazu-shi, Chiba, Koriyama-shi, Fukushima, Kumamoto, Kumamoto-shi, Kumamoto, Kyoto, Kyoto-shi, Kyoto, Mie, Mitaka-shi, Tokyo, Miyazaki, Muroran-shi, Hokkaido, Nagano, Nagasaki, Niigata, Numakunai, Ōita, Oita-shi, Oita,, Okayama, Okinawa, Osaka, Saga, Saitama, Sendai-shi, Miyagi, Shiga, Shimane, Shizuoka, Tamana-shi, Kumamoto, Tochigi, Tokushima, Tokyo, Tottori, Wakayama, Yamagata, Yamaguchi, and Yamato-shi, Kanagawa, JapanSee the 116 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with diabetes of any type who, together with their doctor, have decided to start Awiqli. It is a Japanese real-world study lasting about 1 year.

Age: No age limit.
Sex: All sexes can join.
Disease stage: Any type of diabetes mellitus.
Earlier treatment: Any earlier diabetes treatment is allowed. The decision to start commercially available Awiqli must have been made by the patient (or legal representative) and the doctor before, and independently of, joining the study.

Main reasons for not taking part

Took part in this study before
Took any investigational drug in the 30 days before enrolment
Cannot understand or cooperate because of mental incapacity, unwillingness or language barriers
Has a contraindication listed in the Japanese package insert
Has symptoms of low blood sugar or a history of hypersensitivity to any ingredient of the drug

Read by machine on 12 November 2026.

Where in Japan

Clinic TosakiAichi, JapanContact: Novo NordiskTaking people
Fukuoka Naika Clinic_Internal MedicineAichi, JapanContact: Novo NordiskEnrolling by invitation
Hattori Clinic Chiryu_Diabetes and EndocrinologyAichi, JapanContact: Novo NordiskEnrolling by invitation
Ichinomiyanishi HospitalAichi, JapanContact: Novo NordiskEnrolling by invitation
Inazawa Municipal Hospital_Diabetes and EndocrinologyAichi, JapanContact: Novo NordiskEnrolling by invitation
Miyachi ClinicAichi, JapanContact: Novo NordiskTaking people
Uenishi Internal Medicine ClinicAichi, JapanContact: Novo NordiskTaking people
Kakizaki Tonyobyo Naika ClinicAomori, JapanContact: Novo NordiskTaking people
Ohisama Clinic_AomoriAomori, JapanContact: Novo NordiskEnrolling by invitation
Chiba Central Medical CenterChiba, JapanContact: Novo NordiskEnrolling by invitation
Kimitsu Chuo Hospital_Diabetology and EndocrinologyChiba, JapanContact: Novo NordiskTaking people
Shinmatsudo Central General Hospital_Diabetes and EndocrinologyChiba, JapanContact: Novo NordiskEnrolling by invitation
Hasegawa Medicine Clinic, Internal medicineChitose, Hokkaido, JapanContact: Novo NordiskNot yet recruiting
Soyokaze CardioVascular Medicine and Diabetes CareEhime, JapanContact: Novo NordiskEnrolling by invitation
Clinic Masae MinamiFukuoka, JapanContact: Novo NordiskTaking people
Fukuoka Kieikai Hospital_Diabetes and obesity centreFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Ito Naika Clinic_Internal MedicineFukuoka, JapanContact: Novo NordiskTaking people
Kitakyushu Municipal Medical Center_Endocrinology and DiabetesFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Kokura Memorial Hospital_Diabetes and EndocrinologyFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Kyushu Rosai Hospital_Diabetes and MetabolismFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Okada Naika ClinicFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Steel Memorial Yawata Hospital_Diabetes Internal MedicineFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Tanaka Naika Clinic_Internal MedicineFukuoka, JapanContact: Novo NordiskEnrolling by invitation
Asano NaikaGifu, JapanContact: Novo NordiskEnrolling by invitation
Gifu University Hospital_Diabetes and EndocrinologyGifu, JapanContact: Novo NordiskEnrolling by invitation
Gunma University Hospital_Endocrinology and DiabetesGunma, JapanContact: Novo NordiskEnrolling by invitation
Shimizu NaikaGunma, JapanContact: Novo NordiskEnrolling by invitation
Murakami Memorial Hospital_Diabetes Internal MedicineHiroshima, JapanContact: Novo NordiskEnrolling by invitation
Ito Hiroshi Naika Tonyobyonaika ClinicHokkaido, JapanContact: Novo NordiskEnrolling by invitation
Kagetsu ClinicHokkaido, JapanContact: Novo NordiskEnrolling by invitation
Kurihara NaikaHokkaido, JapanContact: Novo NordiskEnrolling by invitation
Takasawa Diabetes ClinicHokkaido, JapanContact: Novo NordiskEnrolling by invitation
Yoshimura Tonyobyo ClinicHokkaido, JapanContact: Novo NordiskEnrolling by invitation
Hyogo Prefectural Awaji Medical Center_Diabetes and EndocrinologyHyōgo, JapanContact: Novo NordiskEnrolling by invitation
Kagayaki Diabetes and Endocrinology Clinic Sannomiya_Diabetes Internal MedicineHyōgo, JapanContact: Novo NordiskEnrolling by invitation
Matsuda Diabetes ClinicHyōgo, JapanContact: Novo NordiskTaking people
Takabe Diabetes ClinicHyogogoken, JapanContact: Novo NordiskEnrolling by invitation
Itabashi Diabetes and Dermatology Medical ClinicIbaraki, JapanContact: Novo NordiskEnrolling by invitation
Naka Kinen Clinic_Internal medicineIbaraki, JapanContact: Novo NordiskEnrolling by invitation
Ushiku Aiwa General Hospital_Diabetes and MetabolismIbaraki, JapanContact: Novo NordiskEnrolling by invitation
Mitoyo General Hospital_Internal MedicineKagawa, JapanContact: Novo NordiskEnrolling by invitation
Tempozan Clinic of Internal MedicineKagoshima-shi, Kagoshima, JapanContact: Novo NordiskEnrolling by invitation
H.E.C Science Clinic_Internal Medicine, DiabetesKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Hiyoshi Clinic_Diabetes Internal MedicineKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Kikuchi Naika Clinic_KanagawaKanagawa, JapanContact: Novo NordiskTaking people
Shonanisehara Clinic_Internal MedicineKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Takeda ClinicKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Teikyo Univ.HP, Mizonokuchi_Fourth Internal MedicineKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Tokai University Hospital_Nephrology, Endocrinology and MetabolismKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Yokohama Rosai Hospital_Diabetes and EndocrinologyKanagawa, JapanContact: Novo NordiskEnrolling by invitation
Hotaruno hakuyukai Medical Corporation of JapanKisarazu-shi, Chiba, JapanContact: Novo NordiskTaking people
Seino Internal Medicine Clinic_Internal medicineKoriyama-shi, Fukushima, JapanContact: Novo NordiskTaking people
Jinnouchi Hospital_Internal MedicineKumamoto, JapanContact: Novo NordiskTaking people
Kumamoto University Hospital, Diabetes, Metabo and EndoKumamoto-shi, Kumamoto, JapanContact: Novo NordiskEnrolling by invitation
Kamiuchi Naika ClinicKyoto, JapanContact: Novo NordiskEnrolling by invitation
Kyoto University Hospital_Department of Diabetes, EndocrKyoto-shi, Kyoto, JapanContact: Novo NordiskEnrolling by invitation
Japanese Red Cross Ise Hospital_Diabetes and MetabolismMie, JapanContact: Novo NordiskEnrolling by invitation
MG ClinicMie, JapanContact: Novo NordiskEnrolling by invitation
Mie National Hospital_Internal MedicineMie, JapanContact: Novo NordiskEnrolling by invitation
Kanno Naika_Internal MedicineMitaka-shi, Tokyo, JapanContact: Novo NordiskTaking people
Heiwadai Hospital_Diabetes and Internal MedicineMiyazaki, JapanContact: Novo NordiskEnrolling by invitation
Ato internal medicine clinic, internal medicineMuroran-shi, Hokkaido, JapanContact: Novo NordiskEnrolling by invitation
Asama General Hospital_DiabetologyNagano, JapanContact: Novo NordiskEnrolling by invitation
Minamiminowa Clinic_Internal Medicine and Endocrinology and MetabolismNagano, JapanContact: Novo NordiskEnrolling by invitation
Kuriya Clinic_Diabetes and Internal MedicineNagasaki, JapanContact: Novo NordiskEnrolling by invitation
Sasebo City General Hospital_Diabetes and EndocrinologyNagasaki, JapanContact: Novo NordiskEnrolling by invitation
Minagawa Clinic Internal MedicineNiigata, JapanContact: Novo NordiskEnrolling by invitation
Niigata Diabetes Clinic_Diabetes and EndocrinologyNiigata, JapanContact: Novo NordiskEnrolling by invitation
Kitakamiekimae Naika ClinicNumakunai, JapanContact: Novo NordiskTaking people
Okamoto Clinic for Diabetes and EndocrinologyŌita, JapanContact: Novo NordiskTaking people
Abe Diabetes Clinic_Internal MedicineOita-shi, Oita,, JapanContact: Novo NordiskEnrolling by invitation
Okayama Medical Center_Diabetes and EndocrinologyOkayama, JapanContact: Novo NordiskEnrolling by invitation
Chibana ClinicOkinawa, JapanContact: Novo NordiskEnrolling by invitation
Japan Organization of Occupational Health and Safety Osaka Rosai Hospital_Diabetes Internal MedicineOsaka, JapanContact: Novo NordiskEnrolling by invitation
Kansai Electric Power Hospital_Center for DiabetesOsaka, JapanContact: Novo NordiskEnrolling by invitation
Kansai Medical University Medical Center_Cardiology and Endocrinology and MetabolismOsaka, JapanContact: Novo NordiskEnrolling by invitation
Matsuda Gastroenterology and Diabetes Clinic_Internal MedicineOsaka, JapanContact: Novo NordiskTaking people
Ogawa ClinicOsaka, JapanContact: Novo NordiskTaking people
Osaka General Hospital of West Japan Railway Company_Diabetes and MetabolismOsaka, JapanContact: Novo NordiskTaking people
Osaka General Medical Center_Diabetes and EndocrinologyOsaka, JapanContact: Novo NordiskEnrolling by invitation
Takatsuki General Hospital_Diabetes and EndocrinologyOsaka, JapanContact: Novo NordiskEnrolling by invitation
Imari Arita Kyoritsu Hospital_Internal MedicineSaga, JapanContact: Novo NordiskTaking people
Saga Chuo Public Hospital_Diabetes Internal MedicineSaga, JapanContact: Novo NordiskEnrolling by invitation
Asano ClinicSaitama, JapanContact: Novo NordiskEnrolling by invitation
Higashisakado Clinic_Diabetes Internal MedicineSaitama, JapanContact: Novo NordiskEnrolling by invitation
Japanese Red Cross Saitama Hospital_Diabetes and EndocrinologySaitama, JapanContact: Novo NordiskEnrolling by invitation
Saitama Medical Center_Diabetes and EndocrinologySaitama, JapanContact: Novo NordiskEnrolling by invitation
Matsudakai Tsurugaya Clinic, Internal medicineSendai-shi, Miyagi, JapanContact: Novo NordiskEnrolling by invitation
Nagahama City Hospital_Nephrology and MetabolismShiga, JapanContact: Novo NordiskEnrolling by invitation
Yamane HospitalShimane, JapanContact: Novo NordiskTaking people
Yamauchi Naika_Internal MedicineShimane, JapanContact: Novo NordiskEnrolling by invitation
Juntendo University Shizuoka Hospital_Diabetes and EndocrinologyShizuoka, JapanContact: Novo NordiskEnrolling by invitation
Kikuchi Medical ClinicShizuoka, JapanContact: Novo NordiskTaking people
Higashi Diabetes and Cardiovascular Clinic, InternalTamana-shi, Kumamoto, JapanContact: Novo NordiskEnrolling by invitation
Nagasaki Hospital_Internal MedicineTochigi, JapanContact: Novo NordiskEnrolling by invitation
Oyama East Clinic_Internal MedicineTochigi, JapanContact: Novo NordiskEnrolling by invitation
Ooshima ClinicTokushima, JapanContact: Novo NordiskEnrolling by invitation
Aoi Clinic_Diabetes and Internal MedicineTokyo, JapanContact: Novo NordiskEnrolling by invitation
Kanto Central Hospital of the Mutual Aid Association of Public School Teachers_Diabetes and EndocrinologyTokyo, JapanContact: Novo NordiskEnrolling by invitation
KAWASAKI internal medicine clinic & DiabeticTokyo, JapanContact: Novo NordiskEnrolling by invitation
Kudanzaka Hospital_Internal MedicineTokyo, JapanContact: Novo NordiskEnrolling by invitation
Matsuura ClinicTokyo, JapanContact: Novo NordiskTaking people
Mishuku Hospital_Endocrinology and MetabolismTokyo, JapanContact: Novo NordiskEnrolling by invitation
National Center for Global Health and Medicine_Diabetes and EndocrinologyTokyo, JapanContact: Novo NordiskEnrolling by invitation
Okamoto Naika ClinicTokyo, JapanContact: Novo NordiskEnrolling by invitation
Tamacenter Clinic MiraiTokyo, JapanContact: Novo NordiskTaking people
The Jikei University Hospital Dept of Diabetes, MetabolicTokyo, JapanContact: Novo NordiskEnrolling by invitation
Tokai University Hachioji Hospital_Neph.& Endocrinology,Metab.Tokyo, JapanContact: Novo NordiskEnrolling by invitation
Tokyo Kyosai Hospital_Diabetes and EndocrinologyTokyo, JapanContact: Novo NordiskTaking people
Tokyo Women's Medical University_Diabetes and MetabolismTokyo, JapanContact: Novo NordiskEnrolling by invitation
Honda Clinic_Internal MedicineTottori, JapanContact: Novo NordiskTaking people
Wakayama Medical Univercity Hospital_Diabetes and EndocrinologyWakayama, JapanContact: Novo NordiskEnrolling by invitation
Kouchi IinYamagata, JapanContact: Novo NordiskEnrolling by invitation
Tohoku Central Hospital_Diabetes Internal MedicineYamagata, JapanContact: Novo NordiskNot yet recruiting
Kudamatsu Central Hospital_Internal MedicineYamaguchi, JapanContact: Novo NordiskEnrolling by invitation
Tsuruma Kaneshiro Diabetes Clinic_Internal medicineYamato-shi, Kanagawa, JapanContact: Novo NordiskEnrolling by invitation

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it: Novo Nordisk A/S
Trial code: NCT06807190
Record updated: 27 August 2026
Original description: The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.Read full original descriptionShow less
A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); The decision to initiate treatment with commercially available Awiqli has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study; Male or female with no age limitation; Diagnosis of diabetes mellitus. There is no limitation for type of diabetes mellitus and prior treatment for diabetes mellitus.
Exclusion: Previous participation in this study. Participation is defined as having given informed consent in this study; Treatment with any investigational drug within 30 days prior to enrolment into the study; Participants with a history of hypersensitivity to any ingredients of this drug; Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation; Contraindication described in Japanese package insert; Participants showing hypoglycaemic symptoms.
ClinicalTrials.gov NCT06807190